EANS-News: Sangui Bio Tech International Inc. / Biotech enterprise Sangui starts expanding internationally recording large order from Mexico

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Global Expansion/Government Contracts/Sales Progress

Witten (euro adhoc) - Biotech enterprise Sangui starts expanding
internationally recording large order from Mexico Witten, Germany,
December 21, 2012 Effective now, Sangui BioTech International, Inc.
(Symbol: SGBI ) has its wound therapeutic Granulox being sold in
Mexico. Sangui BioTech GmbH has licensed the respective rights to its
affiliate SastoMed GmbH. SastoMed is already distributing Granulox in
Germany. At the outset of the international expansion a large order
could be recorded yielding an expected sales volume of over
EUR500,000. The largest customer purchasing from the first delivery
of Granulox to Mexico is the State of Tamaulipas. Here, governmental
health institutions will be equipped with the wound therapeutic.
Granulox is being applied as a spray. Main indications are chronic
wounds, originating in most cases in lack of oxygen supply (hypoxia)
or insufficient blood flow to the respective part of the body. In
many cases diabetes is the primary disease. Diabetes affects the
blood vessels thus causing circulation disturbances in legs and feet.
Around 37 million treatments per annum occur on a global scale. More
than one fourth of those are being registered in Latin America.
Expansion to Mexico is seen as the first step to addressing this
market. The expansion shall be promoted based on a contractually
agreed cooperation with the Mexico based distribution partner Bio-Mac
Pharma the management of which has a track record of successfully
supporting the sales of other renowned pharmaceutical companies like
Pfizer, Novartis and Schering Plough. Sangui BioTech International,
Inc. ("SGBI") is a holding company the shares of which are being
traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and the
OTC market of Hamburg-Hannover stock exchanges. Its purpose is to
provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety
percent subsidiary of Sangui BioTech International, Inc.

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English